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Background: High failure rates of metal-on-metal (MoM) hip implants prompted regulatory authorities to issue worldwide
safety alerts. Circulating cobalt from these implants causes rare but fatal autopsy-diagnosed cardiotoxicity. There is
concern that milder cardiotoxicity may be common and underrecognized. Although blood metal ion levels are easily
measured and can be used to track local toxicity, there are no noninvasive tests for organ deposition. We sought to detect
correlation between blood metal ions and a comprehensive panel of established markers of early cardiotoxicity.
Methods: Ninety patients were recruited into this prospective single-center blinded study. Patients were divided into
3 age and sex-matched groups according to implant type and whole-blood metal ion levels. Group-A patients had a
ceramic-on-ceramic [CoC] bearing; Group B, anMoM bearing and low bloodmetal ion levels; and Group C, anMoM bearing
and high blood metal-ion levels. All patients underwent detailed cardiovascular phenotyping using cardiac magnetic
resonance imaging (CMR) with T2*, T1, and extracellular volume mapping; echocardiography; and cardiac blood bio-
marker sampling. T2* is a novel CMR biomarker of tissue metal loading.
Results: Blood cobalt levels differed signiﬁcantly among groups A, B, and C (mean and standard deviation [SD], 0.17 ±
0.08, 2.47 ± 1.81, and 30.0 ± 29.1 ppb, respectively) and between group A and groups B and C combined. No signiﬁcant
between-group differences were found in the left atrial or ventricle size, ejection fraction (on CMR or echocardiography), T1
or T2* values, extracellular volume, B-type natriuretic peptide level, or troponin level, and all values were within normal
ranges. There was no relationship between cobalt levels and ejection fraction (R = 0.022, 95% conﬁdence interval [CI] =
20.185 to 0.229) or T2* values (R = 0.108, 95% CI = 20.105 to 0.312).
Conclusions: Using the best available technologies, we did not ﬁnd that high (but not extreme) blood cobalt and
chromium levels had any signiﬁcant cardiotoxic effect on patients with an MoM hip implant. There were negligible-to-weak
correlations between elevated blood metal ion levels and ejection fraction even at the extremes of the 95% CI, which
excludes any clinically important association.
Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
O
ver 1 million patients worldwide have implanted
metal-on-metal (MoM) hip prostheses, predomi-
nantly composed of cobalt-chromium (CoCr) alloy1.
Release of nano-particulate debris and metal ions from im-
plants has been reported to cause harm2. Local soft-tissue
deposition adjacent to the joint3-5 results in high failure rates
of MoM hip implants. This led regulatory agencies to issue
safety alerts against their use6-8, necessitating surveillance that
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includes serial measurement of blood metal ion levels and
cross-sectional imaging to determine whether revision sur-
gery is warranted9.
The relationship between MoM hip implants and sys-
temic toxicity is less clear. Elevated levels of circulating cobalt
have been linked with cardiac, thyroid, and neuro-ocular ab-
normalities in case reports, but causation and prevalence re-
main to be established10-18. Diagnosis of cardiotoxicity requires
invasive myocardial biopsy or postmortem examination, with
no available noninvasive methods for measuring metal depo-
sition. Heart failure is common in the patient population most
likely to undergo hip replacement19, so there is concern that an
association between MoM hip prostheses and heart failure may
be missed. One echocardiography (EKG) study showed a 7%
reduction in left ventricular ejection fraction in MoM-implant
recipients20 (although all values were within the normal range).
More recently, an epidemiological study that compared 121
subjects who had 1 type of MoM hip prosthesis with 3,546
subjects who had a metal-on-plastic (MoP) prosthesis showed
the age-adjusted rate of hospitalization for heart failure to be
equivalent to 1 such hospitalization for every 11 patients21. The
Therapeutic Goods Administration (Australian Department of
Health) consequently published a safety alert pending further
investigation22.
Cardiac magnetic resonance imaging (CMR) is the gold-
standard technique for measuring cardiac volumes and func-
tion. In addition, the CMR T2* method for assessing cardiac
iron has been histologically validated and has become a routine
measure, transforming the management of patients at risk for
iron cardiomyopathy23,24. As cobalt exhibits a magnetic prop-
erty similar to that of iron, T2* mapping has the potential to
noninvasively detect tissue deposition of cobalt in patients with
a failing MoM hip prosthesis, as recently demonstrated by our
group25.
The present study of patients with an MoM hip pros-
thesis was designed to assess the effect of elevated whole-blood
metal ion levels on cardiac function as well as to seek evidence
of cardiac metal ion deposition with gold-standard multi-
modality imaging and measurement of serum biomarkers to
minimize potential bias.
Materials and Methods
Study Design
In this single-center blinded cross-sectional study, all patientsunderwent CMR, transthoracic EKG, and blood sampling
during a single visit (Fig. 1). The research was approved by the
institutional review board and ethics committee (reference: 14/LO/
1722) and was registered in ClinicalTrials.gov (NCT02331264).
The primary outcomes were prespeciﬁed on trial registration.
Setting
Between October 2014 and November 2015, 108 patients were
recruited from specialist outpatient clinics held at the Royal
National Orthopaedic Hospital and cardiac assessment was
performed at the Heart Hospital (both University College
London hospitals, U.K.).
Patient Groups
Patients 18 years of age or older with an MoM or ceramic-on-
ceramic (CoC) hip implant in situ for >12 months were re-
cruited. They were divided into 3 age and sex-matched groups
on the basis of prosthesis type and blood metal ion levels.
Group A consisted of patients with a CoC-bearing implant
and normal whole-blood metal ion levels; Group B, patients
with an MoM implant and low whole-blood metal ion levels
(<7 ppb); and Group C, patients with an MoM implant and
raised whole-blood metal ion levels (‡7 ppb). CoC was chosen
over MoP couplings in Group A because of concerns regarding
metal debris arising through trunnionosis in MoP implants,
and 7 ppb was used as a cutoff point between Groups B and C
as this represents the U.K. Medicines & Healthcare products
Fig. 1
Flow diagram of the study methods. ECHO = echocardiogram, LV = left
ventricular, EF = ejection fraction, ESVi = end systolic volume index, ECV =
extracellular volume, LAVi = left atrial volume index, BNB = B-type natri-
uretic peptide, and Trop I = troponin I.
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Regulatory Agency (MHRA) recommended threshold above
which there may be heightened concern6.
Exclusion criteria were prior hip revision surgery, known
atrial ﬁbrillation or impaired renal function (estimated glomer-
ular ﬁltration rate of <30 mL/min), and standard contraindica-
tions to magnetic resonance imaging (MRI) (e.g., a pacemaker).
Six patients—4 of whom would have been assigned to group A
(CoC) and 1 each of whom, to groups B and C—were excluded
because of arrhythmias (e.g., atrial ﬁbrillation).
All participants gave written informed consent con-
forming to the Declaration of Helsinki (5th revision, 2000).
All tests were performed at a single visit. Study data were
collected and managed using REDCap (Research Electronic
Data Capture software, version 5.9.6, http://www.project-
redcap.org/), with the cardiac investigators blinded to the
study groups during data acquisition and analysis until study
completion.
Transthoracic EKG
EKG was performed using a Vivid E9 ultrasound machine (GE
Healthcare). Measurements were made according to the British
Society of Echocardiography standard protocol26, including
acquisition of standard 2-dimensional views, M-mode, spec-
tral tissue Doppler imaging, and blood ﬂow measurements
(Fig. 2-A).
CMR Acquisition
Patients underwent CMR at 1.5 T (MAGNETOM Avanto;
Siemens Medical). Cardiac volumes and ejection fractions
were calculated conventionally from short-axis cine images.
Bright-blood T2* and precontrast T1 mapping of the my-
ocardium and liver were acquired on a mid-left ventricular short
axis slice and an axial mid-hepatic slice, respectively (Figs. 2-C
and 2-D). As T1 mapping is not fully standardized, we used 2
implementations: modiﬁed look-locker (MOLLI) and short-
ened MOLLI (ShMOLLI) sequences (MyoMaps; Siemens). Late
gadolinium-enhancement images were acquired using amotion-
corrected phase sensitive inversion recovery sequence to identify
focal myocardial ﬁbrosis after administering 0.1 mmol/kg of
gadolinium-based contrast medium (gadoterate meglumine
[Dotarem; Guerbet]). Fifteen minutes after the injection of the
contrast medium, T1 sequences were repeated for extracellular
volume quantiﬁcation (Figs. 3-A, 3-B, and 3-C).
Fig. 2
Comprehensive cardiac assessment included transthoracic EKG (Fig. 2-A), measurement of blood biomarker levels (BNP and troponin I) (Fig. 2-B),
CMR (Fig. 2-C), and late gadolinium-enhancement scar imaging (Fig. 2-D).
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Blood Biomarkers
Blood sampling to measure B-type natriuretic peptide (BNP),
troponin-I, and whole-blood cobalt and chromium levels (Fig.
2-B) was performed before the patients underwent CMR. BNP
and high-sensitivity troponin are the most commonly used bio-
markers in cardiology. They cover a range of cardiac processes,
with BNP measurements used to evaluate myocyte strain and
troponin measurements indicating myocyte death. Both have
prognostic importance.
Whole-blood cobalt and chromium levels weremeasured
using inductively coupled plasma mass spectrometry in the
same U.K. reference laboratory to eliminate interlaboratory
variation. The MHRA advises that measurements of cobalt and
chromium ions be carried out by laboratories participating
in the Trace Elements External Quality Assessment Scheme
(TEQAS). The accuracy and reliability of these measurements
are regularly audited and have demonstrated excellent agree-
ment (96.4%; standard deviation [SD] = 2.23%, coefﬁcient
of variation = 2.3%) across the laboratories27.
Image Analysis
All image acquisition and analyses were performed by ob-
servers blinded to the study groups. Unblinding was performed
by an independent statistician once all data had been acquired
and analyzed, with the data set locked.
Left ventricular volumes, ejection fraction, and mass
were calculated from CMR data using standard techniques and
dedicated software (CMRtools; Cardiovascular Imaging Solu-
tions). Thresholding methods were used, and papillary muscles
were considered part of the left ventricular myocardium. Vol-
umes were subsequently indexed to body surface area. Two of
the authors determined the presence of late gadolinium en-
hancement through visual assessment.
For T2* and T1 measurements, a region of interest was
manually drawn on the interventricular septum on each image,
with care taken to avoid the endocardial and epicardial con-
tours to minimize partial voluming effect. Extracellular volume
was calculated using MOLLI sequences via a fully automated
method that calculates pixel-wise extracellular volume para-
metric maps28, based on the standard formula:
extracellular  volume = ð1 2 hematocritÞ
·

DR1myocardium

DR1blood

where DR1 is the change in R1 from the postcontrast to the
precontrast image, and R1 = 1/T1.
Echocardiographic data were digitally stored for ofﬂine
analysis with EchoPAC dimension software (GE Healthcare).
Conventional analysis of left ventricular structure and systolic
and diastolic function including spectral tissue Doppler pa-
rameters were performed according to guidelines, with values
averaged over 2 cardiac cycles. Tissue Doppler parameters for
lateral and septal walls were averaged to produce a single mar-
ker of systolic longitudinal function.
Study Size
Sample size calculations were based on previously published data20,
which indicated an absolute difference in ejection fraction of 5%
(with a pooled SD of approximately 8%) between patients with an
MoM hip prosthesis and those with a conventional hip prosthesis.
Using an alpha value of 0.05 and a 2:1 sample size ratio between
MoM and CoC prostheses, we needed 62 patients with an MoM
implant and 31 with a CoC implant to have a power of 80% to
Fig. 3
Precontrast (Fig. 3-A) and postcontrast (Fig. 3-B) T1 mapping combined for extracellular volume mapping (Fig. 3-C).
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detect a 5% difference (Cohen delta = 0.63, classiﬁed as a medium
to large effect). The MoM group was divided according to blood
metal levels using 7 ppb as a cutoff6 (yielding approximately a 1:1:1
ratio overall).
Statistical Analysis
The prespeciﬁed primary end points were ejection fraction
(determined with CMR) and T2*measurement. The secondary
end points included left ventricular end systolic volume index,
T1, and extracellular volume measurements with CMR; ejec-
tion fraction and left atrial volume index and left ventricular
long axis function (mean of the lateral and septal S' velocities
measured with EKG); and blood biomarkers.
The 3 groups were assessed for matching using chi-square
tests (or Fisher exact tests when the expected counts were <5) for
binary variables and analysis of variance (ANOVA) for contin-
uous variables. The distribution of the metal ions was not nor-
mal, and the group variances were highly heterogeneous; hence,
nonparametric tests onmedians were used to compare ion levels
between groups. We used parametric and nonparametric test
results to establish whether there was a signiﬁcant difference in
the mean and/or median effect on cardiac function between the
groups. The distributions of the cardiac exposure variables in
each group appeared normal for outcome variables of interest,
with the variance usually constant (according to the Bartlett
test); thus, ANOVA (F test) was conducted for each marker. As
the sample sizes were relatively small, a formal test for normality
was not conducted. However, sensitivity analyses with non-
parametric tests (comparing the median across groups) were
performed to relax the parametric assumption, and they always
conﬁrmed the conclusions obtained for the mean (results not
shown). The presence of signiﬁcant results at a 5% signiﬁcance
level was further assessed by dividing the threshold by the
number of tests conducted (Bonferroni correction).
Correlations between whole-blood metal ion levels and
ejection fraction and T2* values were calculated using the Pear-
son correlation coefﬁcient (with metal ions log-transformed)
and Spearman correlation coefﬁcient (with metal ions on the
original scale).
The minimum detectable effect size was calculated using
Cohen’s d29.
All calculations were performed using Stata 14 (StataCorp).
Results
Patients
Ninety patients completed the study. Baseline patientcharacteristics are shown in Table I. Patients were matched
for age and sex. Group A (CoC; n = 28) had a mean age (and SD)
TABLE I Patient Demographics by Study Group
Demographic All Patients Group A Group B Group C P Value
Sample (no.) 90 28 33 29
Age* (yr) 64.9 ± 10.5 65.3 ± 8.80 61.9 ± 11.9 67.6 ± 10.8 0.115
Sex (F/M) (no.) 60/30 21/7 21/12 18/11 0.525
Time since implantation* (yr) 8.76 ± 2.34 7.86 ± 2.62 9.03 ± 1.87 9.39 ± 2.52 0.041
BMI† (kg/m2) 28 28 (18-38) 28 (20-45) 27 (20-48) 0.929
Diabetes (no.; %) 3; 3 1; 4 1; 3 1; 3 0.982
Hypertension (no.; %) 32; 36 11; 39 12; 36 9; 31 0.715
Hypercholesterolemia (no.; %) 20; 22 9; 32 4; 12 7; 24 0.105
Medications (no.; %)
b blocker 5; 6 2; 7 0 3; 10 0.181
ACE inhibiter‡ 10; 11 5; 18 3; 9 2; 7 0.326
Thiazide diuretic 8; 9 2; 7 4; 12 2; 7 0.741
Calcium channel blocker 15; 17 7; 25 4; 12 4; 14 0.289
Aspirin 3; 3 1; 4 0 2; 7 0.317
Statin 20; 22 9; 32 4; 12 7; 24 0.121
Proton pump inhibitor 18; 20 8; 29 3; 9 7; 24 0.101
Thyroxine 8; 9 4; 14 4; 12 0 0.108
Hemoglobin level† (g/dL) 14 14.1 14.2 13.6 0.134
Cobalt level† (ppb) 10.9 0.17 (0.10-0.47) 2.47 (0.73-6.97) 30.01 (7.54-118) <0.0001
Chromium level† (ppb) 7.7 0.74 (0.53-1.42) 2.84 (0.94-10.5) 19.6 (1.71-69.0) <0.0001
*The values are given as the mean and SD. †The values are given as the mean with or without the range in parentheses. ‡ACE = angiotensin-
converting enzyme.
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of 65.3 ± 8.8 years, and 75% of the patients were female. Group B
(MoMwith a lowmetal-ion level; n= 33) had amean age of 61.9±
11.9 years, and 64% were female. Group C (MoM with a high
metal-ion level; n = 29) had a mean age of 67.6 ± 10.8 years, and
62% were female. The mean cobalt levels in groups A, B, and C
were 0.17 ± 0.08, 2.47 ± 1.81, and 30.0 ± 29.1 ppb, respectively.
The overall mean time from implantation of the pros-
thesis to the date of the scan was slightly shorter in group A
than in group B or C (7.9 ± 2.6 versus 9.0 ± 1.9 and 9.4 ± 2.5
years, F = 3.5, p = 0.041).
Although the groups were not matched for body mass
index (BMI), cardiovascular risk factors, or medications, there
were no signiﬁcant differences between them with regard to
those factors.
CMR
The 3 groups did not differ signiﬁcantly with regard to the
mean left ventricular ejection fraction (70.1% ± 6%, 69.5% ±
7%, and 70.6% ± 5%, p = 0.75; Table II and Fig. 4) or the left
ventricular end systolic volume index (p = 0.86). Additionally,
we found no differences in the left ventricular ejection fraction
or end systolic volume index when we combined groups B and
C and compared the combined group with group A (Table II).
The mean cardiac T2* values were normal in the 3
groups and did not differ signiﬁcantly among them (p = 0.69)
or between the combined MoM group (B and C) and group A
(p = 0.85). All patients with high blood metal levels (Group C)
TABLE II CMR, EKG, and Blood Biomarker Results
P Value
Measurement† Group A (N = 28)* Group B (N = 33)* Group C (N = 29)*
A vs.
B vs. C
A vs.
B and C
CMR
Left ventricular ejection fraction (%) 70 ± 6 69 ± 7 71 ± 5 0.75 0.96
End systolic volume index (mL/m2) 21 ± 6 21 ± 8 20 ± 5 0.86 0.99
T1 MOLLI: heart (NR = 949-1101 ms) (ms) 1,030 ± 42 1,014 ± 33 1,022 ± 37 0.64 0.15
T1 ShMOLLI: heart (NR = 900-1,020 ms) (ms) 961 ± 31 957 ± 30 956 ± 44 0.82 0.54
T2*: heart (normal = >20 ms) (ms) 31 ± 5 31 ± 6 32 ± 6 0.69 0.85
Extracellular volume: heart 0.28 ± 0.03 0.27 ± 0.03 0.29 ± 0.04 0.28 0.62
T1 mapping: liver (ms) 616 ± 72 596 ± 78 584 ± 49 0.21 0.11
T2* mapping: liver (normal = >6.3 ms) (ms) 25 ± 4 26 ± 7 25 ± 5 0.67 0.92
Extracellular volume: liver 0.29 ± 0.04 0.30 ± 0.03 0.30 ± 0.04 0.62 0.36
EKG
Left ventricular end diastolic diameter (mm) 43 ± 9 45 ± 5 45 ± 6 0.26 0.10
Left ventricular end systolic diameter (mm) 28 ± 6 30 ± 4 30 ± 5 0.18 0.06
Left ventricular ejection fraction (%) 65 ± 6 62 ± 7 63 ± 6 0.28 0.12
Left ventricular lateral wall tissue Doppler
imaging (m/s)
0.09 ± 0.02 0.08 ± 0.02 0.09 ± 0.02 0.24 0.16
Left ventricular septal wall tissue Doppler
imaging (m/s)
0.08 ± 0.02 0.07 ± 0.02 0.08 ± 0.01 0.16 0.12
Left atrial volume index (mL/m2) 27 ± 6 28 ± 7 31 ± 8 0.19 0.20
Blood biomarker sampling
BNP (normal = <47 pmol/L) (pmol/L) 11 ± 10 11 ± 8 25 ± 61 0.32 0.52
Troponin (NR = 0-14 ng/L) (ng/L) 7.38 ± 6.9 7.16 ± 5.0 8.62 ± 10.2 0.77 0.78
*Data are presented as the mean and SD. †NR = normal range.
Fig. 4
Scatterplot demonstrating the mean left ventricular ejection fraction
(LVEF), and the SD, for the 3 groups.
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had normal T2* values (>20 ms). The T1 values measured with
both the MOLLI and the ShMOLLI techniques were normal in
the 3 groups and did not differ signiﬁcantly among the groups
(MOLLI: p = 0.64; ShMOLLI: p = 0.82). The extracellular
volume was normal in, and did not differ signiﬁcantly among,
the 3 groups (p = 0.28), with no outliers.
The liver T2* values were normal in all patients. No
differences were identiﬁed among the 3 groups (p = 0.67) or
between the combined MoM group (B and C) and group
A (p = 0.92). The liver T1 value and extracellular volume also
did not differ signiﬁcantly between or among groups (Table II).
Transthoracic EKG
There was no signiﬁcant difference in the left ventricular
ejection fraction among groups A, B, and C (65% ± 6%, 62% ±
7%, and 63% ± 6%, respectively; p = 0.28). Similarly, the left
atrial volume index was similar among the 3 groups (p = 0.19)
with no differences between the combined MoM group (B and
C) and group A (p = 0.20). There were also no between-group
differences in the mean lateral and septal S' velocities (tissue
Doppler imaging) (p = 0.24 and 0.16, respectively).
Blood Biomarkers
There were no signiﬁcant differences in the BNP level among
groups A, B, and C (11, 11, and 25 pg/mL, respectively). Although
the mean BNP level was highest in group C, the difference failed
to reach signiﬁcance (F = 1.17, p = 0.32). The troponin levels
also did not differ signiﬁcantly among the groups (p = 0.77).
EKG
All study participants had a resting 12-lead EKG. In 5 par-
ticipants (4 in group B and 1 in group C), the EKG demon-
strated left bundle branch block morphology (QRS duration
of >120 ms). There were no ST or T-wave abnormalities, or
changes reﬂecting previous cardiac events such as myocardial
infarction.
Metal Ions and Cardiac Function: Dose Response
A dose-response linear correlation analysis was conducted us-
ing the Pearson coefﬁcient to determine whether there was
a relationship across groups between blood cobalt and chro-
mium levels and left ventricular ejection fraction and T2*
values. There was no signiﬁcant linear correlation between the
blood cobalt level (log scale) and the left ventricular ejection
fraction (R = 0.022, 95% conﬁdence interval [CI] =20.185 to
0.229; p = 0.83) or the T2* value (R = 0.108, 95% CI =20.105
to 0.312; p = 0.32). Similarly, no signiﬁcant correlation was
found between the blood chromium level and the left ven-
tricular ejection fraction (R= 0.047, 95%CI=20.162 to 0.251;
p = 0.66) or the T2* value (R = 0.065, 95% CI = 20.148 to
0.272; p = 0.55) (Fig. 5).
Whole-blood metal levels were non-normally distrib-
uted, unlike the left ventricular ejection fraction and the T2*
value, and log-transforms attenuated without circumventing
the lack of normality. Hence, to avoid an assumption of nor-
mality, the Spearman correlation coefﬁcient was also calcu-
lated, and it showed no signiﬁcant correlation between the
cobalt level and the left ventricular ejection fraction (rho =
0.038, 95% CI =20.170 to 0.243; p = 0.72), between the cobalt
level and the T2* value (rho = 0.074, 95% CI = 20.139 to
0.280; p = 0.50), between the chromium level and the left
ventricular ejection fraction (rho = 0.058, 95% CI =20.151 to
0.262; p = 0.59), or between the chromium level and the T2*
value (rho = 0.012, 95% CI = 20.200 to 0.222; p = 0.92).
Fig. 5
Correlation plots with line of best ﬁt. Whole-blood cobalt and chromium levels are compared with the left ventricular ejection fraction (LVEF; top row) and
T2* values (bottom row). Pearson correlation coefﬁcients (R values) are provided for each.
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Discussion
There is increasing concern regarding the effects of systemiccobalt and chromium toxicity in patients with MoM hip
implants. Although the evidence for toxicity is limited, patient
and surgeon anxiety is fueled by increasing numbers of case
reports of end-organ damage and mortality10. In this study, we
investigated the effects of metal ions on cardiac function in 3
distinct groups of patients deﬁned by the type of hip implant
and the level of circulating blood cobalt. Using 2 independent
cardiac imaging techniques (including the gold standard, CMR),
we failed to ﬁnd a signiﬁcant change in cardiac function in
patients exposed to elevated metal ion levels. There was no
signiﬁcant correlation between elevated blood metal ion levels
and cardiac function; even at the extremes of the 95% CI
around the correlation coefﬁcients, the correlations were neg-
ligible to weak.
Our conﬁdence in these results is based on the strengths
of our study methodology, which included the use of both
CMR and EKG as well as a meticulous trial design. We ensured
a prespeciﬁed recruitment number, data acquisition in a dedicated
cardiac imaging center separate from the recruiting center, and a
cardiac care team completely blinded to the study groups (during
both acquisition and analysis) until the independent statistician
returned the results.
Tissue-mapping techniques also failed to identify any
demonstrable metal deposition from circulating cobalt ions
in the cardiac or liver tissues. Although we recently demon-
strated25 that T2* mapping can detect biopsy-proven CoCr, the
lack of demonstrable tissue deposition in the present study may
be due to differences in the physical chemistry of cobalt ions
compared with that of cobalt and chromium in combination.
However, the fact that iron can be detected in the heart and
liver using T2* mapping, and we previously detected CoCr
(colocalized) in the liver25, indicates that the reasonwhy the T2*
ﬁndings were negative in all cases in the present study was
either that the test is too insensitive or no deposition was oc-
curring. T2* should be considered a candidate biomarker,
which, if it had differed between the groups, would have in-
dicated the biological process of deposition. The lack of func-
tional consequences (demonstrated by complementary and
independent imaging modalities [CMR and EKG] and 2 blood
biomarkers) and the lack of positive T2* ﬁndings, although not
deﬁnitive, are reassuring.
A potential for cardiotoxicity from metal implants, as
demonstrated by an inferior left ventricular ejection fraction,
has been previously reported. However, these reports are limited
to individual case reports10-18 and to studies20 with less rigorous
methodology. For example, Prentice et al.20 used EKG, which has
a higher interobserver variability than CMR, and that may ac-
count for the difference between their and our ﬁndings. We
conclude that individual case reports of heart failure (mainly in
patients with extreme ion levels) are not likely to be “the tip of
the iceberg” or to indicate an unrecognized epidemic of occult
MoM-related heart failure.
The pathophysiology behind a possible link between el-
evated blood cobalt levels and cardiac toxicity is unclear. Sug-
gested theories include cobalt interference with cardiac
myocyte oxygen uptake and transmembrane transport sys-
tem disruption30. Histopathological ﬁndings in cobalt-
related cardiac toxicity include myoﬁbrillar hypertrophy,
interstitial ﬁbrosis, and muscle ﬁber degeneration31. How-
ever, calciﬁed ﬁbrils or other deposits within myoﬁbrils are
often absent, differentiating cobalt-induced cardiomyopathy
from other etiologies13. It has been postulated that cobalt-
related cardiac toxicity is due to additional predisposing
factors, including poor nutrition and excessive alcohol in-
take as was seen in the Quebec beer-drinkers cobalt car-
diomyopathy epidemic (in which foam stabilizer contained
10 times the usual quantity of cobalt)31. Recent case reports
of cardiac toxicity in association with MoM hip implants
mainly involved patients with extremely elevated blood co-
balt levels (>100 ppb)10. Because of current national sur-
veillance programs, such patients are now likely to have
undergone revision surgery, with presumed reduction in
their risk of systemic toxicity.
We believe that these ﬁndings offer reassurance to sur-
geons and will help them counsel the >1 million patients
worldwide withMoM hip implants. Additional work is needed,
particularly from large-volume linkage studies currently under
way internationally. n
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